AlphaNa Bioscience announced the initiation of a multicenter Phase IIb clinical trial of AFN0328 injection, a therapeutic mRNA vaccine targeting human papillomavirus (HPV)-associated diseases. The trial was launched at Peking University People's Hospital, the lead clinical site, with participation from more than 30 clinical centers across China.

AlphaNa Bioscience founder Professor Yucai Wang and collaborators have published a research article in Science, revealing a previously unrecognized gut–liver immune regulatory axis that controls the clearance and delivery efficiency of therapeutic vectors

AlphaNa Bioscience and its founder, Professor Yucai Wang, and colleagues have published a research article in the Journal of the American Chemical Society (JACS), reporting a data-driven strategy for designing mRNA delivery systems with organ-selective targeting capabilities.

Shanghai, China – January 29, 2026 – The National Major Science and Technology Project for the Prevention and Control of Emerging, Re-emerging, and Major Infectious Diseases — titled "Basic and Applied Research on Trained Immunity in the Prevention and Control of Emerging

Shanghai Jiao Tong University has launched a national research initiative focused on trained immunity for emerging and re-emerging infectious diseases, bringing together leading academic institutions and biotechnology partners, including AlphaNa Bioscience. The initiative aims to advance fundamental discoveries and translational technologies for next-generation approaches in infectious disease prevention and immune modulation.